ArticleScientific reports2021

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.

Giovanna Elisiana Carpagnano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.